Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics among patients receiving rituximab or anti-TNF agents, and standardized differences

From: Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

  Trimmed population Stratified-matched population
  Rituximab
(n = 265)
Anti-TNF (n = 737) Standardized difference Rituximab
(n = 205)
Anti-TNF
(n = 205)
Standardized difference
Demographics
 White, % 87.6 83.5 0.114 84.4 87.3 0.084
 Female, % 81.1 79.2 0.049 82.9 81.0 0.051
 Age, mean (SD), years 57.8 (11.7) 56.1 (12.4) 0.139 57.6 (11.7) 58.0 (11.5) 0.037
Insurance
 Medicare, % 37.7 29.4 0.176 33.7 39.0 0.111
 Medicaid, % 7.2 6.4 0.032 7.3 6.3 0.039
 Private insurance, % 76.6 78.7 0.050 76.1 74.6 0.034
 No insurance, % 1.1 2.3 0.090 1.5 1.5 0.000
History of comorbidities
 Cardiovascular disease, % 11.3 7.3 0.137 9.8 11.7 0.063
 Cancer, % 9.4 7.7 0.061 10.2 8.8 0.050
 Diabetes, % 9.8 10.7 0.030 10.2 10.7 0.016
Clinical characteristics
 Disease duration, mean (SD), years 15.4 (10.2) 11.4 (9.4) 0.408 14.6 (10.3) 15.1 (10.5) 0.047
 Tender joint count, mean (SD) 9.6 (7.3) 8.7 (7.3) 0.117 9.5 (7.2) 9.1 (7.8) 0.058
 Swollen joint count, mean (SD) 8.0 (5.6) 7.5 (5.7) 0.097 7.9 (5.5) 7.4 (5.8) 0.086
 Patient global assessment, mean (SD) 54.3 (23.6) 50.6 (25.0) 0.154 53.2 (23.4) 52.7 (25.5) 0.023
 Physician global assessment, mean (SD) 42.7 (20.2) 39.3 (20.1) 0.169 42.3 (19.7) 39.8 (19.1) 0.130
 Patient pain, mean (SD) 56.5 (24.5) 53.2 (25.5) 0.132 55.3 (24.8) 53.0 (26.2) 0.093
 Disability index (mHAQ), mean (SD) 0.78 (0.5) 0.64 (0.5) 0.270 0.74 (0.5) 0.72 (0.5) 0.040
 Clinical Disease Activity Index, mean (SD) 27.3 (12.5) 25.2 (11.9) 0.172 27.0 (12.0) 25.7 (12.3) 0.100
Prior medication use
 Prior nbDMARDs, n, mean 1.6 1.1 0.396 1.4 1.4 0.031
 Prior use of ≥2 anti-TNF agents, % 63.0 26.6 0.786 54.6 54.6 0.000
 Prior use of non–anti-TNF biologic agents, % 40.8 13.0 0.657 31.7 33.2 0.031
Concomitant medications
 Prednisone, % 43.8 29.3 0.303 39.0 38.5 0.010
 Methotrexate, % 57.7 55.9 0.037 57.1 51.7 0.108
 Non-methotrexate nbDMARD, % 29.1 24.8 0.095 29.8 30.2 0.011
  1. Anti-TNF Anti–tumor necrosis factor, mHAQ modified Health Assessment Questionnaire, nbDMARD nonbiologic disease-modifying antirheumatic drug